Show simple item record

dc.contributor.authorXing, Mingzhao
dc.contributor.authorAlzahrani, Ali S
dc.contributor.authorCarson, Kathryn A
dc.contributor.authorShong, Young Kee
dc.contributor.authorKim, Tae Yong
dc.contributor.authorViola, David
dc.contributor.authorElisei, Rossella
dc.contributor.authorBendlova, Bela
dc.contributor.authorYip, Linwah
dc.contributor.authorMian, Caterina
dc.contributor.authorVianello, Federica
dc.contributor.authorTuttle, R Michael
dc.contributor.authorRobenshtok, Eyal
dc.contributor.authorFagin, James A
dc.contributor.authorPuxeddu, Efisio
dc.contributor.authorFugazzola, Laura
dc.contributor.authorCzarniecka, Agnieszka
dc.contributor.authorJarzab, Barbara
dc.contributor.authorO'Neill, Christine J
dc.contributor.authorSywak, Mark S
dc.contributor.authorLam, Alfred K
dc.contributor.authorRiesco-Eizaguirre, Garcilaso
dc.contributor.authorSantisteban, Pilar
dc.contributor.authorNakayama, Hirotaka
dc.contributor.authorClifton-Bligh, Roderick
dc.contributor.authorTallini, Giovanni
dc.contributor.authorHolt, Elizabeth H
dc.contributor.authorSykorova, Vlasta
dc.date.accessioned2018-10-04T03:16:54Z
dc.date.available2018-10-04T03:16:54Z
dc.date.issued2015
dc.identifier.issn0732-183X
dc.identifier.doi10.1200/JCO.2014.56.8253
dc.identifier.urihttp://hdl.handle.net/10072/125092
dc.description.abstractPurpose: To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillary thyroid cancer (PTC). Patients and Methods: This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months). Results: The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAF V600E mutation–positive and 11.6% (125 of 1,082) of BRAF V600E mutation–negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation–positive versus –negative patients (P < .001), with a hazard ratio (HR) of 1.82 (95% CI, 1.46 to 2.28), which remained significant in a multivariable model adjusting for patient sex and age at diagnosis, medical center, and various conventional pathologic factors. Significant association between BRAF mutation and PTC recurrence was also found in patients with conventionally low-risk disease stage I or II and micro-PTC and within various subtypes of PTC. For example, in BRAF mutation–positive versus –negative follicular-variant PTC, recurrence occurred in 21.3% (19 of 89) and 7.0% (24 of 342) of patients, respectively, with recurrence rates of 53.84 (95% CI, 34.34 to 84.40) versus 19.47 (95% CI, 13.05 to 29.04) per 1,000 person-years (P < .001) and an HR of 3.20 (95% CI, 1.46 to 7.02) after adjustment for clinicopathologic factors. BRAF mutation was associated with poorer recurrence-free probability in Kaplan-Meier survival analyses in various clinicopathologic categories. Conclusion: This large multicenter study demonstrates an independent prognostic value of BRAF V600E mutation for PTC recurrence in various clinicopathologic categories.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherAmerican Society of Clinical Oncology
dc.publisher.placeUnited States
dc.relation.ispartofpagefrom42
dc.relation.ispartofpageto50
dc.relation.ispartofissue1
dc.relation.ispartofjournalJournal of Clinical Oncology
dc.relation.ispartofvolume33
dc.subject.fieldofresearchOncology and Carcinogenesis not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchcode111299
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1112
dc.titleAssociation Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dc.description.versionPublished
gro.rights.copyright© 2015 American Society of Clinical Oncology. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
gro.hasfulltextFull Text
gro.griffith.authorLam, Alfred K.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record